Consensus Myriad Genetics, Inc.

Stocks

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 21:00:00 15/10/2026 BST			5-day change	1st Jan Change
4.350 ^USD	+4.82%		+3.57%	-29.27%

10-08	Sophia Genetics, Myriad Genetics Collaborate on Prostate Cancer Biomarker	MT
10-08	Myriad Genetics, Inc. and SOPHiA GENETICS Announce Collaboration to Advance Prostate Genomic Instability Score Technology with AstraZeneca	CI

Evolution of the Average Target: Myriad Genetics, Inc.

Evolution of the Target Price: Myriad Genetics, Inc.

Changes in Analyst Recommendations: Myriad Genetics, Inc.

ea61f5f1eaa7d987873ab267b.uJ9KaEGzqCamGvjUbhYR8x-rNgAJrIgc7YDRAC-MlG0.1tArWQzV8VHDVLS_XUxZw2vqZUdc59Axn62TZ2nJ2B3x1CMJOeWRTPAttQ~b2fb8c4bcfbe933a856e1ddd9582b6b0

Analysts' recommendations: Myriad Genetics, Inc.

09-09	UBS Adjusts Price Target on Myriad Genetics to $3.60 From $6, Keeps Neutral Rating	MT
09-01	Myriad Genetics Shares Fall After Piper Sandler Downgrade	MT
09-01	Piper Sandler Downgrades Myriad Genetics to Underweight From Overweight	MT
02-24	UBS Adjusts Price Target on Myriad Genetics to $6 From $8, Maintains Neutral Rating	MT
11-04	UBS Adjusts Myriad Genetics Price Target to $8 From $6, Maintains Neutral Rating	MT
07/08/25	UBS Adjusts Price Target on Myriad Genetics to $6 From $7, Maintains Neutral Rating	MT
06/08/25	Top Midday Gainers	MT
21/05/25	Myriad Genetics Shares Fall After Downgrade From Scotiabank	MT
21/05/25	Scotiabank Downgrades Myriad Genetics to Sector Perform From Sector Outperform, Adjusts Price Target to $6 From $20	MT
19/05/25	Morgan Stanley Cuts Price Target on Myriad Genetics to $7 From $16, Maintains Equalweight Rating	MT
08/05/25	Wolfe Research Downgrades Myriad Genetics to Peer Perform From Outperform	MT
07/05/25	UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating	MT
07/05/25	Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22	MT
09/04/25	Guggenheim Downgrades Myriad Genetics to Neutral From Buy	MT
12/03/25	Myriad Genetics Shares Rise After Upgrade From Piper Sandler	MT
12/03/25	Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50	MT
25/02/25	UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating	MT
09/12/24	Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30	MT
18/11/24	Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating	MT
19/09/24	Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target	MT
19/09/24	Morgan Stanley Initiates Myriad Genetics at Equalweight	MT
28/08/24	Wells Fargo Initiates Myriad Genetics at Overweight With $35 Price Target	MT
27/06/24	Scotiabank Initiates Myriad Genetics at Sector Outperform	MT
13/05/24	Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating	MT
29/01/24	Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating	MT

More recommendations

Diagnostic & Testing Substances

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
MYRIAD GENETICS, INC.	-	-5.46%
ABBOTT LABORATORIES		+15.32%
MEDTRONIC PLC		+9.38%
STRYKER CORPORATION		+23.66%
ESSILORLUXOTTICA		+50.61%
CENCORA, INC.		+8.42%
HOYA CORPORATION		+21.02%
BECTON, DICKINSON AND COMPANY		+0.16%
IDEXX LABORATORIES, INC.		+28.17%
MEDLINE INC.		+21.47%
Average		+17.28%
Weighted average by Cap.		+19.06%